CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT. The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.

In today’s practice of interventional radiology, clinicians use image guiding technologies to deliver targeted, minimally invasive treatments to help treat a wide range of medical conditions – from cancer care and vascular disease to common health concerns that affect quality of life for both men and women alike. Among the emerging treatments in interventional radiology today, prostatic artery embolization (PAE) has been shown to be an effective treatment for symptomatic benign prostatic hyperplasia (BPH), or an enlarged prostate - the most common prostate condition for men older than age 50.1 The procedure involves targeted release of microscopic particles into the arteries that feed the prostate. The particles stop blood flow into the gland helping to decrease its size and relieve troubling BPH symptoms without any cutting, use of laser or tissue removal. In order for the PAE procedure to be successful, clinicians need to be able to identify the correct arteries and vascular anatomy feeding the prostate in order to deliver precise and targeted treatment.

As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software. Embo ASSIST AI builds on Embo ASSIST software with AI-based automation designed to automatically segment vascular structures to facilitate embolization workflow planning, as well as help clinicians visualize and anticipate the destination of potential injections.

Scientific studies have shown that the use of Embo ASSIST enables users performing PAE to:

Reduce patient dose by 44% (Air Kerma) and 58% (Peak Skin Dose);2
Reduce fluoroscopy time by 27% and overall procedure time by 21 minutes (20%);2
Improve anatomy understanding in 46% of cases versus raw cone-beam computed tomography (CBCT), with four times more secondary branches found versus digital subtraction angiography (DSA);3 and
Reduce PAE patient dose (DAP) by 70% and improved PAE technical success from 70% without software to 90% with software.4

Operating Room Homepage